Skip to main content
TipRanks
Go Ultimate75% OFF

Mediwound (M8W) Q3 2026 Earnings Report

0 Followers

DE:M8W Q3 2026 EPS Results

Actual EPS
-EUR 0.59
Consensus EPS
-EUR 0.64
Beat/Miss
Beat by +EUR 0.05
One Year Ago EPS
-EUR 0.22

DE:M8W Q3 2026 Revenue Results

Actual Revenue
EUR 3.24M
Expected Revenue
EUR 6.10M
Beat/Miss
Missed by -EUR 2.86M
YoY Revenue Growth
-34.19%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/12/2026
Time
Before Open
Conference Call
Thursday, November 12, 2026
DE:M8W Upcoming Earnings

Mediwound's next earnings date is estimated for March 18, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DE:M8W Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 12, 2026|% Change Since:-1.64%|
Earnings Call Sentiment|Neutral

The call had meaningful operational and development positives, including strong NexoBrid demand, positive VALUE trial safety reviews, progress toward enrollment and additional funding for NexoBrid programs. However, these were offset by lower revenue, widening operating and adjusted EBITDA losses, substantial cash burn, supply-constrained product sales, and uncertainty around U.S. government funding that affects the 2026 outlook and a significant portion of 2027 guidance. Overall, the positive and negative factors were relatively balanced.

Company Guidance

Management said the VALUE trial’s current enrollment target is 216 patients across approximately 40 sites, with enrollment expected to be completed by the end of the first quarter of 2027; the interim sample size reassessment is planned after treatment of 140-ish patients to confirm 85% statistical power, followed by around 3 months of treatment and another couple of weeks of aggregating the data, with top line results expected in mid-2027. Management said 95% of the sites are open, expanded NexoBrid facility work is expected to be completed in the fourth quarter of 2026, commercial supply remains expected in the second half of 2027, and there is some cushion in that 6-month period, but supply is not expected earlier. The company said its 2026 revenue outlook depends on ongoing U.S. government funding discussions, while a substantial portion of anticipated 2026 revenue is tied to the planned U.S.-based facility; the $24 million to $26 million guidance has a significant part tied to that facility. Management also described approximately $1 billion in U.S. peak sales across 3 chronic wound categories, a 50-patient DFU study, and an additional $3.3 million award bringing the room-temperature-stable NexoBrid program’s total budget to $21.8 million.

  • VALUE Trial Enrollment Remains on TrackMediWound said enrollment in the global Phase III VALUE trial for venous leg ulcers remains on track for completion by the end of the first quarter of 2027. The current target is 216 patients across approximately 40 sites, and management said approximately 95% of sites are currently open.
  • Positive VALUE Trial Safety ReviewThe Independent Data and Safety Monitoring Board completed its prespecified periodic review of the VALUE trial, identified no safety concerns, and recommended continuing the trial as planned without modifications. The next reviews are expected in early January 2027 and at the end of the first quarter of 2027.
  • Expected VALUE Top-Line Results in Mid-2027Assuming the current 216-patient design, management expects approximately three months of treatment after enrollment completion plus a couple of weeks for data aggregation, with top-line results expected in mid-2027.
  • Expansion of EscharEx Development ProgramsMediWound is preparing clinical studies of EscharEx in pressure ulcers and diabetic foot ulcers. The pressure ulcer study is investigator-initiated and expected to be a small open-label trial, while the diabetic foot ulcer study is a 50-patient, double-blinded trial supported by the European Innovation Council and strategic collaborators.
  • Strong U.S. NexoBrid Commercial PerformanceVericel reported NexoBrid's strongest quarter since launch, with its highest quarterly revenue to date, the highest number of ordering burn centers, and the highest number of hospital orders. More new centers ordered NexoBrid in the first nine months of 2026 than in all of 2025.
  • Broadening NexoBrid Commercial ReachMore than 80 centers have placed NexoBrid orders to date, with approximately 70 placing repeat orders. Government procurement under Vericel's BARDA contract began in the third quarter and is expected to continue through the fourth quarter of 2026 and the first quarter of 2027.
  • NexoBrid Development Programs Supported by BARDAMediWound continues to support two NexoBrid development programs under its master service agreement with Vericel: indication expansion to acute trauma injuries associated with thermal burns and development of a new stable formulation. Both programs are covered by the Vericel-BARDA contract.
  • Additional $3.3 Million Nondilutive FundingThe Department of War awarded MediWound an additional $3.3 million in nondilutive funding to advance a room-temperature-stable NexoBrid formulation for battlefield burn care. The program's total budget is now $21.8 million and is intended to support development through submission of an IND application.
  • Current NexoBrid Facility Maintained GMP CertificationMediWound's current NexoBrid facility successfully completed routine GMP inspections by the FDA and the Israeli Ministry of Health, with the Israeli inspection also conducted on behalf of the EMA. The facility's GMP certification is valid for an additional two years.
  • Expanded Manufacturing Facility ProgressingMediWound expects to complete operational modifications recommended during the prior EMA preaudit in the fourth quarter of 2026. Commercial supply from the expanded facility remains targeted for the second half of 2027, subject to regulatory review and approval.
  • Higher Third-Quarter Gross MarginThird-quarter gross profit was $1.0 million, with gross margin of 28.5%, compared with gross profit of $0.9 million and gross margin of 16.5% in the prior-year period. Management attributed the improvement primarily to a higher contribution from royalty revenue, which carries a higher gross margin.
  • Lower Third-Quarter SG&A ExpenseThird-quarter SG&A expense declined to $3.4 million from $4.0 million in the third quarter of 2025, primarily due to lower marketing expenses.
  • EscharEx Investment and Strategic Commercial PotentialManagement said EscharEx is a strategic asset for large wound-care companies and described it as the only late-stage BLA candidate of its kind to the company's knowledge. MediWound cited approximately $1 billion in projected U.S. peak sales across venous leg ulcers, diabetic foot ulcers, and pressure ulcers, and said eight of the nine larger wound-care companies are collaborating with it.
  • Recent Financing Strengthened the Balance SheetMediWound closed an underwritten public offering in November 2026, including full exercise of the option, for gross proceeds of $17.25 million. Warrant exercises generated $2.0 million during the first nine months, with an additional $1.1 million received after quarter end.

DE:M8W Earnings History

DE:M8W earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 18, 20272026 (Q4)-0.54--0.51――
Nov 12, 20262026 (Q3)-0.64-0.59-0.22-170.83% (-0.37)
Aug 13, 20262026 (Q2)-0.69-0.70-1.1237.40% (+0.42)
May 27, 20262026 (Q1)-0.59-0.21-0.06-228.57% (-0.15)
Mar 05, 20262025 (Q4)-0.59-0.51-0.33-55.56% (-0.18)
Nov 20, 20252025 (Q3)-0.74-0.22-0.8975.51% (+0.67)
Aug 14, 20252025 (Q2)-0.52-1.12-0.62-80.88% (-0.50)
May 21, 20252025 (Q1)-0.60-0.06-0.9593.33% (+0.89)
Mar 19, 20252024 (Q4)-0.52-0.33-0.17-89.47% (-0.15)
Nov 26, 20242024 (Q3)-0.43-0.89-0.22-308.33% (-0.67)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed